Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 176Thoracic 10Head & Neck 8Tumor-Agnostic 2Breast 2Other solid neoplasm 1Genitourinary 1

Conditions

HER2-positive 1

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × S 1 (combination) × Other solid neoplasm × Clear all
NCT05218148 2022-04-06

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

ChineseAMS

Phase 2 Unknown
44 enrolled
GastrointestinalOther solid neoplasm

HER2-positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡